Abstract | OBJECTIVE: To compare extra- lipid effects of statins and fibrates in relation to the baseline metabolic status of patients. RESEARCH DESIGN AND METHODS: RESULTS: CONCLUSIONS: The presence of pre-diabetes potentiates metabolic syndrome-induced abnormalities in plasma markers of inflammation and hemostasis and in monocyte secretory function. Both atorvastatin and fenofibrate exhibit multidirectional pleiotropic effects in subjects with metabolic syndrome, the strength of which seem to be partially determined by the type of pre-diabetes.
|
Authors | Robert Krysiak, Anna Gdula-Dymek, Ryszard Bachowski, Boguslaw Okopien |
Journal | Diabetes care
(Diabetes Care)
Vol. 33
Issue 10
Pg. 2266-70
(Oct 2010)
ISSN: 1935-5548 [Electronic] United States |
PMID | 20587704
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticholesteremic Agents
- Cytokines
- Heptanoic Acids
- Plasminogen Activator Inhibitor 1
- Pyrroles
- Factor VII
- Fibrinogen
- C-Reactive Protein
- Atorvastatin
- Fenofibrate
|
Topics |
- Anticholesteremic Agents
(adverse effects, therapeutic use)
- Atorvastatin
- C-Reactive Protein
(metabolism)
- Cytokines
(metabolism)
- Factor VII
(metabolism)
- Fenofibrate
(adverse effects, therapeutic use)
- Fibrinogen
(metabolism)
- Heptanoic Acids
(adverse effects, therapeutic use)
- Humans
- Metabolic Syndrome
(drug therapy, metabolism)
- Plasminogen Activator Inhibitor 1
(metabolism)
- Prediabetic State
(chemically induced, metabolism)
- Pyrroles
(adverse effects, therapeutic use)
|